Form 4: Equillium Principal Accounting Officer Executes Stock Sale
Statement of Changes in Beneficial Ownership
Principal Accounting Officer Tom Penny exercised options and sold 65,000 shares of Equillium, Inc. common stock.
Summary
- Tom Penny, Principal Accounting Officer of Equillium, Inc., exercised options to acquire 65,000 shares of common stock at a price of $0.785 per share.
- Following the acquisition, the reporting person sold the entire block of 65,000 shares at a weighted average price of $2.95 per share.
- The transactions were executed on May 28, 2026, pursuant to a Rule 10b5-1 trading plan adopted on October 10, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a routine exercise of vested equity compensation.
Positives
- The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.
Negatives
- The reporting person reduced their direct beneficial ownership of Equillium, Inc. common stock to zero following the sale.
Risks
- Insider selling can sometimes be perceived by the market as a lack of confidence in the company's short-term growth prospects, despite the use of a 10b5-1 plan.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider sales executed via 10b5-1 plans are common in the biotechnology sector, often serving as a liquidity event for executives rather than a signal of fundamental business deterioration.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining regulatory compliance.
Stakeholder Impact
- Shareholders should note the reduction in insider ownership, though the use of a 10b5-1 plan mitigates concerns regarding potential insider trading.
Key Dates
| Date | Description |
|---|---|
| 2025-10-10 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-05-28 | Date of the option exercise and subsequent sale of shares. |
| 2026-05-29 | Date the Form 4 was signed and filed. |
Keywords
Equillium, EQ, Insider Trading, Form 4, Stock Option Exercise, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.